Acute myeloid leukaemia (Q36663603)

15 August 2017

1 reference

title

Acute myeloid leukaemia (English)

1 reference

15 August 2017

1 reference

2

Hartmut Döhner

1 reference

15 August 2017

1

Elihu Estey

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

368

1 reference

15 August 2017

issue

9550

1 reference

15 August 2017

page(s)

1894-1907

1 reference

Chromosomal instability in acute myelocytic leukemia and myelodysplastic syndrome patients among atomic bomb survivors

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Chernobyl fallout, nuclear plants and leukaemia: review of recent literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Radiation-induced acute myeloid leukaemia and other cancers in commercial jet cockpit crew: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Hematopoietic malignancies and related disorders among benzene-exposed workers in China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Tobacco and the risk of acute leukaemia in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Smoking and risk of acute myeloid leukemia: results from a Los Angeles County case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Benzene, NQO1, and genetic susceptibility to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Genetics of myeloid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Genetics of myeloid malignancies: pathogenetic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

The core-binding factor leukemias: lessons learned from murine models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Epigenetics in human disease and prospects for epigenetic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Methylation profiling in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Active immunotherapy trials on acute lymphoid leukemia lymphosarcoma and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Vaccination for leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Dendritic cell immunotherapy for the treatment of neoplastic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Imatinib Mesylate — Uncovering a Fast Track to Adaptive Immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Chemokines, chemokine receptors and hematopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

The effect of chemotherapy on acute leukemia in the human

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Clinical importance of cytogenetics in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Gene expression profiling in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognostically useful gene-expression profiles in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Risk assessment in patients with acute myeloid leukemia and a normal karyotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Radioimmunotherapy for acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Treatment of relapsed and refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Minimal residual disease monitoring by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969780-8

7 January 2021

10.1016/S0140-6736(06)69780-8

Identifiers

DOI

1 reference

15 August 2017

1 reference